 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||||| Nano Covax / Nanogen Biopharma
Enrollment closed, Trial completion date, Trial primary completion date: Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19 (clinicaltrials.gov) - Nov 4, 2022
P3, N=13000, Active, not recruiting, Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company
Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: Jul 2022 --> Dec 2022
- || Nano Covax / Nanogen Biopharma
Clinical, P1 data, Journal: Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial. (Pubmed Central) - May 24, 2022
P1/2
Up to day 90, Nanocovax was found to be safe, well tolerated, and induced robust immune responses. This work was funded by the Coalition for Epidemic Preparedness Innovations (CEPI), the Ministry of Science and Technology of Vietnam, and Nanogen Pharmaceutical Biotechnology JSC.
- | Nano Covax / Nanogen Biopharma
Preclinical, Journal: Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19. (Pubmed Central) - Jan 7, 2022
albino) and rats (Rattus norvegicus). These preclinical results indicate that Nanocovax is safe and effective.
- || Nano Covax / Nanogen Biopharma
Vietnam har en lignende vax i fase 3 as we speak - Nanocovax. (Twitter) - Jul 21, 2021
- |||||||||| Nano Covax / Nanogen Biopharma
New P3 trial: Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19 (clinicaltrials.gov) - Jun 11, 2021
P3, N=13000, Recruiting, Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company
- ||||| Nano Covax / Nanogen Biopharma
New P1/2 trial: A Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers (clinicaltrials.gov) - Dec 24, 2020
P1/2, N=620, Recruiting, Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company